Stephan Rosenkranz

List of Publications by Year
in descending order

110 papers	10,464 citations	41344 49 h-index	33894 99 g-index
124 all docs	124 docs citations	124 times ranked	13161 citing authors

#	Article	IF	Citations
1	ESC guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 2â€"care pathways, treatment, and follow-up. European Heart Journal, 2022, 43, 1059-1103.	2.2	111
2	Selonsertib in adults with pulmonary arterial hypertension (ARROW): a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Respiratory Medicine,the, 2022, 10, 35-46.	10.7	17
3	Detection of patients with chronic thromboembolic pulmonary hypertension by volumetric iodine quantification in the lungâ€"a case control study. Quantitative Imaging in Medicine and Surgery, 2022, 12, 1121-1129.	2.0	5
4	Temporal trends in pulmonary arterial hypertension: results from the COMPERA registry. European Respiratory Journal, 2022, 59, 2102024.	6.7	57
5	COMPERA 2.0: a refined four-stratum risk assessment model for pulmonary arterial hypertension. European Respiratory Journal, 2022, 60, 2102311.	6.7	124
6	Optimal follow-up after acute pulmonary embolism: a position paper of the European Society of Cardiology Working Group on Pulmonary Circulation and Right Ventricular Function, in collaboration with the European Society of Cardiology Working Group on Atherosclerosis and Vascular Biology, endorsed by the European Respiratory Society. European Heart Journal, 2022, 43, 183-189.	2.2	83
7	The REPAIR Study. JACC: Cardiovascular Imaging, 2022, 15, 240-253.	5.3	28
8	The impact of comorbidities on selexipag treatment effect in patients with pulmonary arterial hypertension: insights from the <scp>GRIPHON</scp> study. European Journal of Heart Failure, 2022, 24, 205-214.	7.1	22
9	Coagulation-independent effects of thrombin and Factor Xa: role of protease-activated receptors in pulmonary hypertension. Cardiovascular Research, 2022, 118, 3225-3238.	3.8	3
10	European Society of Cardiology guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 1â€"epidemiology, pathophysiology, and diagnosis. Cardiovascular Research, 2022, 118, 1385-1412.	3.8	27
11	Was Paul Wood wrong about pre-capillary pulmonary hypertension protecting against pulmonary congestion in left heart disease?. European Heart Journal, 2022, 43, 3432-3434.	2.2	6
12	Spectral Detector CT-Derived Pulmonary Perfusion Maps and Pulmonary Parenchyma Characteristics for the Semiautomated Classification of Pulmonary Hypertension. Frontiers in Cardiovascular Medicine, 2022, 9, 835732.	2.4	3
13	Prognostic value of improvement endpoints in pulmonary arterial hypertension trials: A COMPERA analysis. Journal of Heart and Lung Transplantation, 2022, 41, 971-981.	0.6	9
14	FGF21 modulates mitochondrial stress response in cardiomyocytes only under mild mitochondrial dysfunction. Science Advances, 2022, 8, eabn7105.	10.3	23
15	Chronic thromboembolic pulmonary hypertension and impairment after pulmonary embolism: the FOCUS study. European Heart Journal, 2022, 43, 3387-3398.	2.2	69
16	Prognostic Power of Pulmonary Arterial Compliance Is Boosted by a Hemodynamic Unloading Test With Glyceryl Trinitrate in Heart Failure Patients With Post-capillary Pulmonary Hypertension. Frontiers in Cardiovascular Medicine, 2022, 9, 838898.	2.4	0
17	Profiles and treatment patterns of patients with pulmonary arterial hypertension on monotherapy at experienced centres. ESC Heart Failure, 2022, 9, 2873-2885.	3.1	5
18	Current and future treatments of pulmonary arterial hypertension. British Journal of Pharmacology, 2021, 178, 6-30.	5.4	104

#	Article	IF	Citations
19	Riociguat: Clinical research and evolving role in therapy. British Journal of Clinical Pharmacology, 2021, 87, 2645-2662.	2.4	18
20	Switching to riociguat versus maintenance therapy with phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension (REPLACE): a multicentre, open-label, randomised controlled trial. Lancet Respiratory Medicine,the, 2021, 9, 573-584.	10.7	85
21	Quality of Life 3 and 12 Months Following Acute Pulmonary Embolism. Chest, 2021, 159, 2428-2438.	0.8	34
22	Pulmonary vascular resistance predicts mortality in patients with pulmonary hypertension associated with interstitial lung disease: results from the COMPERA registry. European Respiratory Journal, 2021, 58, 2101483.	6.7	48
23	Ferric carboxymaltose in patients with pulmonary arterial hypertension and iron deficiency: a longâ€term study. Journal of Cachexia, Sarcopenia and Muscle, 2021, 12, 1501-1512.	7.3	18
24	Disrupted PI3K subunit p110Î± signaling protects against pulmonary hypertension and reverses established disease in rodents. Journal of Clinical Investigation, 2021, 131, .	8.2	12
25	Stamp2 Protects From Maladaptive Structural Remodeling and Systolic Dysfunction in Post-Ischemic Hearts by Attenuating Neutrophil Activation. Frontiers in Immunology, 2021, 12, 701721.	4.8	0
26	Less loop diuretic use in patients on sacubitril/valsartan undergoing remote pulmonary artery pressure monitoring. ESC Heart Failure, 2021, , .	3.1	4
27	k-t accelerated multi-VENC 4D flow MRI improves vortex assessment in pulmonary hypertension. European Journal of Radiology, 2021, 145, 110035.	2.6	6
28	Pulmonary hypertension associated with left-sided heart failure. Current Opinion in Cardiology, 2020, 35, 610-619.	1.8	13
29	Idiopathic pulmonary arterial hypertension phenotypes determined by cluster analysis from the COMPERA registry. Journal of Heart and Lung Transplantation, 2020, 39, 1435-1444.	0.6	104
30	Right ventricular dysfunction and long-term risk of death. Cardiovascular Diagnosis and Therapy, 2020, 10, 1646-1658.	1.7	12
31	The six-transmembrane protein Stamp2 ameliorates pulmonary vascular remodeling and pulmonary hypertension in mice. Basic Research in Cardiology, 2020, 115, 68.	5.9	7
32	Pulmonary Hypertension in Adults with Congenital Heart Disease: Real-World Data from the International COMPERA-CHD Registry. Journal of Clinical Medicine, 2020, 9, 1456.	2.4	21
33	Pharmacological Agents Targeting Thromboinflammation in COVID-19: Review and Implications for Future Research. Thrombosis and Haemostasis, 2020, 120, 1004-1024.	3.4	206
34	Identifying potential parameters associated with response to switching from a PDE5i to riociguat in RESPITE. International Journal of Cardiology, 2020, 317, 188-192.	1.7	5
35	Pulmonary artery pressureâ€guided therapy in ambulatory patients with symptomatic heart failure: the <scp>CardioMEMS E</scp>uropean <scp>M</scp>onitoring <scp>S</scp>tudy for <scp>H</scp>eart <scp>F</scp>ailure (<scp>MEMSâ€HF</scp>). European Journal of Heart Failure, 2020, 22, 1891-1901.	7.1	142
36	Systemic Consequences of Pulmonary Hypertension and Right-Sided Heart Failure. Circulation, 2020, 141, 678-693.	1.6	139

#	Article	IF	Citations
37	COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up. Journal of the American College of Cardiology, 2020, 75, 2950-2973.	2.8	2,392
38	Whole-Body Vibration Therapy in Patients with Pulmonary Hypertension and Right Heart Failure: Lessons from a Pilot Study. , 2020, , 355-362.		0
39	Diagnostic and Therapeutic Gaps inÂPatients With HeartÂFailure and ChronicÂObstructive PulmonaryÂDisease. JACC: Heart Failure, 2019, 7, 823-833.	4.1	55
40	Clinical outcomes stratified by baseline functional class after initial combination therapy for pulmonary arterial hypertension. Respiratory Research, 2019, 20, 208.	3.6	16
41	Patients with pulmonary arterial hypertension with and without cardiovascular risk factors: Results from the AMBITION trial. Journal of Heart and Lung Transplantation, 2019, 38, 1286-1295.	0.6	62
42	Diagnosis of pulmonary hypertension using spectral-detector CT. International Journal of Cardiology, 2019, 285, 80-85.	1.7	14
43	Therapeutic potential of phosphodiesterase type 5 inhibitors in heart failure with preserved ejection fraction and combined post- and pre-capillary pulmonary hypertension. International Journal of Cardiology, 2019, 283, 152-158.	1.7	38
44	Pulmonary hypertension due to left heartÂdisease. European Respiratory Journal, 2019, 53, 1801897.	6.7	389
45	Risk assessment in pulmonary arterial hypertension. European Respiratory Journal, 2018, 51, 1702606.	6.7	67
46	Pulmonary vascular indices and survival in left heart disease: illusion of conclusion?. European Journal of Heart Failure, 2018, 20, 256-259.	7.1	3
47	Riociguat for the Treatment of Raynaudâ€™s Phenomenon: A Single-Dose, Double-Blind, Randomized, Placebo-Controlled Cross-Over Pilot Study (DIGIT). Clinical Drug Investigation, 2018, 38, 1061-1069.	2.2	11
48	Cologne consensus conference on pulmonary hypertension â€“ Update 2018. International Journal of Cardiology, 2018, 272, 1-3.	1.7	10
49	Risk assessment in medically treated chronic thromboembolic pulmonary hypertension patients. European Respiratory Journal, 2018, 52, 1800248.	6.7	61
50	Targeted therapy of pulmonary arterial hypertension: Updated recommendations from the Cologne Consensus Conference 2018. International Journal of Cardiology, 2018, 272, 37-45.	1.7	56
51	Right Heart Catheterization for the Diagnosis of Pulmonary Hypertension. Heart Failure Clinics, 2018, 14, 467-477.	2.1	49
52	Pulmonary hypertension associated with left heart disease: Updated Recommendations of the Cologne Consensus Conference 2018. International Journal of Cardiology, 2018, 272, 53-62.	1.7	56
53	Pulmonary hypertension in heart failure with preserved ejection fraction: a plea for proper phenotyping and further researchâ€. European Heart Journal, 2017, 38, ehw597.	2.2	83
54	Cardiopulmonary exercise testing for detecting pulmonary arterial hypertension in systemic sclerosis. Heart, 2017, 103, 774-782.	2.9	59

#	Article	IF	Citations
55	Oscillatory whole-body vibration improves exercise capacity and physical performance in pulmonary arterial hypertension: a randomised clinical study. Heart, 2017, 103, 592-598.	2.9	34
56	Pulmonary Hypertensionâ€“Back to the Future. Revista Espanola De Cardiologia (English Ed), 2017, 70, 901-904.	0.6	1
57	Echocardiographic estimation of left ventricular and pulmonary pressures in patients with heart failure and preserved ejection fraction: a study utilizing simultaneous echocardiography and invasive measurements. European Journal of Heart Failure, 2017, 19, 1651-1660.	7.1	89
58	RESPITE: switching to riociguat in pulmonary arterial hypertension patients with inadequate response to phosphodiesterase-5 inhibitors. European Respiratory Journal, 2017, 50, 1602425.	6.7	113
59	HipertensiÃ³n pulmonar. Regreso al futuro. Revista Espanola De Cardiologia, 2017, 70, 901-904.	1.2	2
60	ER stress-induced aggresome trafficking of HtrA1 protects against proteotoxicity. Journal of Molecular Cell Biology, 2017, 9, 516-532.	3.3	9
61	What can we learn from pulmonary function testing in heart failure?. European Journal of Heart Failure, 2017, 19, 1222-1229.	7.1	46
62	Mortality in pulmonary arterial hypertension: prediction by the 2015 European pulmonary hypertension guidelines risk stratification model. European Respiratory Journal, 2017, 50, 1700740.	6.7	489
63	An official European Respiratory Society statement: pulmonary haemodynamics during exercise. European Respiratory Journal, 2017, 50, 1700578.	6.7	222
64	Pulmonary Hypertension. Deutsches Ärzteblatt International, 2017, 114, 73-84.	0.9	87
65	Predictors of long-term outcomes in patients treated with riociguat for pulmonary arterial hypertension: data from the PATENT-2 open-label, randomised, long-term extension trial. Lancet Respiratory Medicine,the, 2016, 4, 361-371.	10.7	97
66	Initial combination therapy with ambrisentan and tadalafil and mortality in patients with pulmonary arterial hypertension: a secondary analysis of the results from the randomised, controlled AMBITION study. Lancet Respiratory Medicine,the, 2016, 4, 894-901.	10.7	59
67	Late outcomes after acute pulmonary embolism: rationale and design of FOCUS, a prospective observational multicenter cohort study. Journal of Thrombosis and Thrombolysis, 2016, 42, 600-609.	2.1	50
68	Pre-Capillary, Combined, and Post-Capillary Pulmonary Hypertension. Journal of the American College of Cardiology, 2016, 68, 368-378.	2.8	244
69	Predictors of Permanent Pacemaker Implantation After Transcatheter Aortic Valve Replacement With the SAPIEN 3. JACC: Cardiovascular Interventions, 2016, 9, 2200-2209.	2.9	173
70	Case report: Subjective loss of performance after pulmonary embolism in an athleteâ€“ beyond normal values. BMC Pulmonary Medicine, 2016, 16, 21.	2.0	5
71	Transfemoral transcatheter aortic valve implantation in a patient with multiple endovascular aortic stents â€“ a case report. Journal of Cardiothoracic Surgery, 2016, 11, 24.	1.1	1
72	Pioglitazone alleviates cardiac and vascular remodelling and improves survival in monocrotaline induced pulmonary arterial hypertension. Naunyn-Schmiedeberg's Archives of Pharmacology, 2016, 389, 369-379.	3.0	34

#	Article	IF	Citations
73	Left ventricular heart failure and pulmonary hypertension. European Heart Journal, 2016, 37, 942-954.	2.2	486
74	Right heart catheterisation: best practice and pitfalls in pulmonary hypertension. European Respiratory Review, 2015, 24, 642-652.	7.1	147
75	CT-proET1 predicts pulmonary hemodynamics in Scleroderma-associated pulmonary hypertension. Clinical Research in Cardiology, 2015, 104, 525-529.	3.3	1
76	Genetic Ablation of PDGF-Dependent Signaling Pathways Abolishes Vascular Remodeling and Experimental Pulmonary Hypertension. Arteriosclerosis, Thrombosis, and Vascular Biology, 2015, 35, 1236-1245.	2.4	42
77	Class IA Phosphatidylinositol 3-Kinase Isoform p110Î± Mediates Vascular Remodeling. Arteriosclerosis, Thrombosis, and Vascular Biology, 2015, 35, 1434-1444.	2.4	13
78	Pulmonary hypertension 2015: current definitions, terminology, and novel treatment options. Clinical Research in Cardiology, 2015, 104, 197-207.	3.3	50
79	Loss of UCP2 Attenuates Mitochondrial Dysfunction without Altering ROS Production and Uncoupling Activity. PLoS Genetics, 2014, 10, e1004385.	3.5	63
80	Response to Letters Regarding Article, â€œAnticoagulation and Survival in Pulmonary Arterial Hypertension: Results From the Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension (COMPERA)â€• Circulation, 2014, 130, e110-2.	1.6	5
81	Anticoagulation and Survival in Pulmonary Arterial Hypertension. Circulation, 2014, 129, 57-65.	1.6	317
82	Ferric carboxymaltose improves exercise capacity and quality of life in patients with pulmonary arterial hypertension and iron deficiency: A pilot study. International Journal of Cardiology, 2014, 175, 233-239.	1.7	78
83	Acute Hemodynamic Effects of Riociguat in Patients With Pulmonary Hypertension Associated With Diastolic Heart Failure (DILATE-1). Chest, 2014, 146, 1274-1285.	0.8	214
84	Pulmonary Arterial Hypertension. Journal of the American College of Cardiology, 2013, 62, D51-D59.	2.8	432
85	Elderly patients diagnosed with idiopathic pulmonary arterial hypertension: Results from the COMPERA registry. International Journal of Cardiology, 2013, 168, 871-880.	1.7	357
86	Vardenafil for the Treatment of Raynaud Phenomenon: A Randomized, Double-blind, Placebo-Controlled Crossover Study. Archives of Internal Medicine, 2012, 172, 1182-4.	3.8	47
87	Imatinib mesylate for the treatment of pulmonary arterial hypertension. Expert Opinion on Investigational Drugs, 2012, 21, 119-134.	4.1	58
88	Therapeutic potential of sildenafil in patients with heart failure and reactive pulmonary hypertension. International Journal of Cardiology, 2012, 154, 205-206.	1.7	28
89	Cologne Consensus Conference on pulmonary hypertension. International Journal of Cardiology, 2011, 154, S1-S2.	1.7	4
90	Treatment of pulmonary arterial hypertension (PAH): Updated Recommendations of the Cologne Consensus Conference 2011. International Journal of Cardiology, 2011, 154, S20-S33.	1.7	46

#	Article	IF	Citations
91	Pulmonary hypertension due to left heart disease: Updated Recommendations of the Cologne Consensus Conference 2011. International Journal of Cardiology, 2011, 154, S34-S44.	1.7	29
92	Transforming Growth Factor Î²1 Oppositely Regulates the Hypertrophic and Contractile Response to Î²-Adrenergic Stimulation in the Heart. PLoS ONE, 2011, 6, e26628.	2.5	44
93	The Arg389Gly Î²1-adrenoceptor gene polymorphism influences the acute effects of Î²-adrenoceptor blockade on contractility in the human heart. Clinical Research in Cardiology, 2011, 100, 641-647.	3.3	13
94	Hypoxia Enhances Platelet-derived Growth Factor Signaling in the Pulmonary Vasculature by Down-Regulation of Protein Tyrosine Phosphatases. American Journal of Respiratory and Critical Care Medicine, 2011, 183, 1092-1102.	5.6	73
95	Profilin-1 Is Expressed in Human Atherosclerotic Plaques and Induces Atherogenic Effects on Vascular Smooth Muscle Cells. PLoS ONE, 2010, 5, e13608.	2.5	49
96	PDGF-BB protects cardiomyocytes from apoptosis and improves contractile function of engineered heart tissue. Journal of Molecular and Cellular Cardiology, 2010, 48, 1316-1323.	1.9	41
97	Beta1-Adrenoceptor Polymorphism Predicts Flecainide Action in Patients with Atrial Fibrillation. PLoS ONE, 2010, 5, e11421.	2.5	17
98	Significant improvement of right ventricular function by imatinib mesylate in scleroderma-associated pulmonary arterial hypertension. Clinical Research in Cardiology, 2009, 98, 265-267.	3.3	49
99	Influence of Cell Treatment with PDGF-BB and Reperfusion on Cardiac Persistence of Mononuclear and Mesenchymal Bone Marrow Cells after Transplantation into Acute Myocardial Infarction in Rats. Cell Transplantation, 2009, 18, 847-853.	2.5	38
100	Pulmonary hypertension: current diagnosis and treatment. Clinical Research in Cardiology, 2007, 96, 527-541.	3.3	63
101	PI3-kinase/Akt-dependent antiapoptotic signaling by the PDGF Î± receptor is negatively regulated by Src family kinases. FEBS Letters, 2006, 580, 6769-6776.	2.8	23
102	Phosphodiesterase Type 5 Inhibition Is a Novel Therapeutic Option in Raynaud Disease. Archives of Internal Medicine, 2006, 166, 231.	3.8	80
103	Phosphodiesterase type 5 inhibitor sildenafil citrate does not potentiate the vasodilative properties of nebivolol in rat aorta. Life Sciences, 2006, 78, 1103-1107.	4.3	8
104	Systematic Evaluation of Anti-apoptotic Growth Factor Signaling in Vascular Smooth Muscle Cells. Journal of Biological Chemistry, 2005, 280, 14168-14176.	3.4	47
105	The Arg389Gly ??1-adrenoceptor gene polymorphism determines contractile response to catecholamines. Pharmacogenetics and Genomics, 2004, 14, 711-716.	5.7	56
106	Sildenafil Improved Pulmonary Hypertension and Peripheral Blood Flow in a Patient with Scleroderma-Associated Lung Fibrosis and the Raynaud Phenomenon. Annals of Internal Medicine, 2003, 139, 871.	3.9	69
107	Src Family Kinases Negatively Regulate Platelet-derived Growth Factor Î± Receptor-dependent Signaling and Disease Progression. Journal of Biological Chemistry, 2000, 275, 9620-9627.	3.4	52
108	Identification of the Receptor-associated Signaling Enzymes That Are Required for Platelet-derived Growth Factor-AA-dependent Chemotaxis and DNA Synthesis. Journal of Biological Chemistry, 1999, 274, 28335-28343.	3.4	73

#	Article	IF	Citations
109	Evidence for Distinct Signaling Properties and Biological Responses Induced by the PDGF Receptor Î± and Î² Subtypes. Growth Factors, 1999, 16, 201-216.	1.7	190
110	A Role for Src in Signal Relay by the Platelet-derived Growth Factor Î± Receptor. Journal of Biological Chemistry, 1998, 273, 5908-5915.	3.4	76